The clinical impact of crizotinib on central nervous system progression in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Nov 2017 New trial record